Breaking News Instant updates and real-time market news.

CBAY

CymaBay

$6.86

0.13 (1.93%)

, ICPT

Intercept

$90.75

-7.37 (-7.51%)

07:14
09/14/17
09/14
07:14
09/14/17
07:14

Intercept Ocaliva dynamics highlight PBC opportunity, says Oppenheimer

Oppenheimer analyst Jay Olson says the Dear Doctor letter for Intercept's (ICPT) Ocaliva raises awareness of unmet medical need for patients with primary biliary cholangitis, or PBC. Since patients with Child-Pugh B/C cirrhosis were not studied in Ocaliva trials, the analyst believes the FDA's collaboration with Intercept to leverage PK modeling for dosing guidance which is included in the label and emphasized in the Dear Doctor letter highlights the importance of providing novel treatments to PBC patients. Olson expects these events to have a positive impact on the treatment of all PBC patients, and says CymaBay (CBAY) may benefit from these dynamics. He reiterates an Outperform rating and $15 price target on CymaBay's shares.

CBAY

CymaBay

$6.86

0.13 (1.93%)

ICPT

Intercept

$90.75

-7.37 (-7.51%)

  • 25

    Sep

CBAY CymaBay
$6.86

0.13 (1.93%)

08/23/17
LEER
08/23/17
INITIATION
Target $12
LEER
Outperform
CymaBay initiated with an Outperform at Leerink
Leerink analyst Joseph Schwartz started CymaBay with an Outperform rating and $12 price target, noting that the company is currently developing seladelpar for the lead indication of primary biliary cholangitis, an autoimmune disease that causes progressive destruction of the bile ducts in the liver.
08/18/17
RHCO
08/18/17
INITIATION
RHCO
Buy
CymaBay initiated with a Buy at SunTrust
SunTrust analyst Edward Nash started coverage of CymaBay with a $15 price target and a Buy rating. He is upbeat on the outlook for the company's seladelpar, a treatment for a rare liver disease called primary biliary cholangitis. According to the analyst ,the drug has "well defined approvable endpoints and a primed commercial opportunity,"
08/11/17
IFSG
08/11/17
DOWNGRADE
Target $13
IFSG
Outperform
CymaBay downgraded to Outperform from Strong Buy at IFS Securities
IFS Securities analyst David Bouchey downgraded CymaBay to Outperform from Strong Buy, saying he sees now as a good time to step back with additional news flow not expected to pick until 2018. He lowered his price target on CymaBay to $13 from $18.
07/25/17
PIPR
07/25/17
NO CHANGE
Target $12
PIPR
Overweight
CymaBay price target raised to $12 from $6.50 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for CymaBay Therapeutics to $12 to reflect increasing value for seladelpar. Importantly, no liver transaminase signals nor drug-induced pruritus were observed in the "positive" Phase II data in 24 primary biliary cholangitis patients receiving seladelpar, the analyst contends. He reiterates an Overweight rating on CymaBay shares.
ICPT Intercept
$90.75

-7.37 (-7.51%)

09/13/17
JMPS
09/13/17
NO CHANGE
Target $150
JMPS
Outperform
Intercept letter doesn't change fundamental view of Ocaliva, says JMP Securities
JMP Securities analyst Liisa Bayko said the warning letter sent by Intercept to health care providers regarding post-marketing reports of liver issues and death in certain PBC patients highlights risks that were already known and doesn't change her fundamental view on Ocaliva. The analyst, who sees little read through to the ongoing Phase 3 REGENERATE trial in NASH patients and views yesterday's drop in Intercept shares as an overreaction, keeps an Outperform rating and $150 price target on the stock.
09/13/17
BMOC
09/13/17
NO CHANGE
BMOC
Intercept should be bought on weakness, says BMO Capital
BMO Capital analyst M. Ian Somaiya says the letter sent by Intercept to healthcare providers regarding its Ocaliva drug relates to failure by doctors to adhere to dose adjustments recommended in its label. Since no new adverse events were cited in the letter, the analyst does not expect any changes to the label. He continues to expect strong Ocaliva prescriptions to result in the company reporting beat and raise Q3 results, and he recommends buying the stock on weakness. He keeps a $221 price target and an Outperform rating on the stock.
09/13/17
MSCO
09/13/17
NO CHANGE
MSCO
Underweight
Intercept talks raise concern of potentially larger issue, says Morgan Stanley
Morgan Stanley analyst Andrew Berens noted that Intercept attended the firm's healthcare conference and discussed its recently sent "Dear Healthcare Provider" letter regarding liver toxicity seen with Ocaliva in some PBC patients. Discussion at the event suggests Ocaliva may have direct effect on liver toxicity in the presence of cholestasis and/or high drug levels, according to Berens, who sees this issue having significant implications for the drug, especially in NASH patients, he tells investors. Berens keeps an Underweight rating and $75 price target on Intercept shares, which closed yesterday down 13.5% at $98.12.
09/13/17
SBSH
09/13/17
NO CHANGE
Target $150
SBSH
Buy
Intercept price target lowered to $150 from $240 at Citi
Citi analyst Joel Beatty lowered his price target for Intercept Pharmaceuticals to $150 saying a "more robust" competitive landscape in both primary biliary cholangitis and nonalcoholic steatohepatitis could limit peak sales of Ocaliva. While the drug appears to be effective and safe in NASH, its overall profile may "not be strong enough to drive a rapid increase" in the NASH diagnosis rate upon approval, limiting the drug's first mover advantage, Beatty tells investors in a research after the company sent a letter to health care providers warning that serious liver injuries, including death, have been reported in primary biliary cholangitis patients dosed with Ocaliva at higher than recommended levels. Safety concerns are likely to remain an overhang on the shares at least until results from the Phase 3 Regenerate trial in the first half of 2019, which is beyond the 12 month time horizon of the new target price, Beatty writes. He keeps a Buy rating on Intercept. The stock yesterday closed down 13.5%, or $15.36, to $98.12.

TODAY'S FREE FLY STORIES

RXDX

Ignyta

$16.65

0.4 (2.46%)

20:30
10/19/17
10/19
20:30
10/19/17
20:30
Syndicate
Ignyta 10M share Secondary priced at $16.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 20

    Oct

PG

Procter & Gamble

$91.59

-0.4904 (-0.53%)

, GE

General Electric

$23.58

0.46 (1.99%)

20:25
10/19/17
10/19
20:25
10/19/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$91.59

-0.4904 (-0.53%)

GE

General Electric

$23.58

0.46 (1.99%)

HON

Honeywell

$143.62

0.18 (0.13%)

SLB

Schlumberger

$64.50

-1.41 (-2.14%)

STI

SunTrust

$59.11

-0.18 (-0.30%)

SYF

Synchrony

$31.71

0.2 (0.63%)

CFG

Citizens Financial

$37.43

0.25 (0.67%)

KSU

Kansas City Southern

$103.78

0.97 (0.94%)

GNTX

Gentex

$20.66

0.2 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 02

    Nov

WILC

G. Willi-Food

$5.85

-0.14 (-2.34%)

18:35
10/19/17
10/19
18:35
10/19/17
18:35
Hot Stocks
G. Willi-Food receives notice from Arla Food ending distribution agreement »

G. Willi-Food's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIC

Macquarie Infrastructure

$71.26

-0.46 (-0.64%)

18:30
10/19/17
10/19
18:30
10/19/17
18:30
Hot Stocks
Macquarie Infrastructure CEO to become CEO of Macquarie Atlas Roads in 2018 »

Macquarie Infrastructure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

BIDU

Baidu

$264.52

-4.45 (-1.65%)

18:30
10/19/17
10/19
18:30
10/19/17
18:30
Hot Stocks
Baidu collaborating with China's BAIC Group and King Long for autonomous driving »

Baidu signed strategic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

IBKC

Iberiabank

$80.15

0.05 (0.06%)

18:27
10/19/17
10/19
18:27
10/19/17
18:27
Hot Stocks
IBERIABANK to acquire Gibraltar Private Bank & Trust »

IBERIABANK Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 15

    Nov

  • 28

    Nov

VBTX

Veritex

$27.04

-0.02 (-0.07%)

18:20
10/19/17
10/19
18:20
10/19/17
18:20
Hot Stocks
Veritex receives regulatory approval for Liberty Bancshares merger »

Veritex Holdings, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

BHP

BHP Billiton

$41.56

0.06 (0.14%)

18:03
10/19/17
10/19
18:03
10/19/17
18:03
Hot Stocks
BHP Billiton CEO sees challenges around geopolitical uncertainty remaining »

In annual shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRRX

Durect

$1.97

0.03 (1.55%)

17:59
10/19/17
10/19
17:59
10/19/17
17:59
Hot Stocks
Durect: Phase 3 clinical trial for POSIMIR did not meet primary endpoint »

Durect reported that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTNP

Titan Pharmaceuticals

$1.90

-0.1 (-5.00%)

17:49
10/19/17
10/19
17:49
10/19/17
17:49
Hot Stocks
Titan Pharmaceuticals presents non-clinical data from liothyronine implant »

Titan Pharmaceuticals is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSA

MSA Safety

$82.20

1.37 (1.69%)

17:46
10/19/17
10/19
17:46
10/19/17
17:46
Earnings
MSA Safety reports Q3 EPS 92c, consensus 80c »

Reports Q3 revenue $296M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

SKX

Skechers

$24.03

-1.06 (-4.22%)

, CAI

CAI International

$31.38

-0.05 (-0.16%)

17:41
10/19/17
10/19
17:41
10/19/17
17:41
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

SKX

Skechers

$24.03

-1.06 (-4.22%)

CAI

CAI International

$31.38

-0.05 (-0.16%)

PYPL

PayPal

$67.25

-0.01 (-0.01%)

MXIM

Maxim Integrated

$50.09

0.24 (0.48%)

IMDZ

Immune Design

$5.50

-1.05 (-16.03%)

NCR

NCR Corp.

$37.05

-0.26 (-0.70%)

TACO

Del Taco

$15.39

-0.01 (-0.06%)

ATHN

athenahealth

$116.41

-4.37 (-3.62%)

ISRG

Intuitive Surgical

$357.46

3.09 (0.87%)

ETFC

E-Trade

$43.69

-0.23 (-0.52%)

CELG

Celgene

$135.96

-1.21 (-0.88%)

PBMD

Prima BioMed

$2.36

-0.02 (-0.84%)

AAXN

Axon

$24.62

-0.37 (-1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 21

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 29

    Nov

DGX

Quest Diagnostics

$93.23

1.18 (1.28%)

17:37
10/19/17
10/19
17:37
10/19/17
17:37
Hot Stocks
Quest Diagnostics acquires Cleveland HeartLab, terms not disclosed »

Advantage Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

  • 30

    Nov

AAXN

Axon

$24.62

-0.37 (-1.48%)

17:34
10/19/17
10/19
17:34
10/19/17
17:34
Hot Stocks
Axon says now aware of comment letter over SEC's review of 10-K, 10-Q »

Axon Enterprise said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPMX

BioPharmX

17:29
10/19/17
10/19
17:29
10/19/17
17:29
Syndicate
Breaking Syndicate news story on BioPharmX »

BioPharmX files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBVX

MabVax Therapeutics

$0.74

0.0248 (3.47%)

17:29
10/19/17
10/19
17:29
10/19/17
17:29
Syndicate
Breaking Syndicate news story on MabVax Therapeutics »

MabVax Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBKC

Iberiabank

$80.15

0.05 (0.06%)

17:28
10/19/17
10/19
17:28
10/19/17
17:28
Earnings
Iberiabank reports Q3 non-GAAP EPS $1.00, consensus $1.16 »

Reports Q3 core revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 15

    Nov

  • 28

    Nov

DRRX

Durect

$1.97

0.03 (1.55%)

17:28
10/19/17
10/19
17:28
10/19/17
17:28
Hot Stocks
Breaking Hot Stocks news story on Durect »

Durect trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCP

Quality Care Properties

$16.26

0.07 (0.43%)

17:26
10/19/17
10/19
17:26
10/19/17
17:26
Hot Stocks
Quality Care Properties provides update on HCR ManorCare »

Quality Care Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTR

Frontier Communications

$11.48

0.02 (0.17%)

, CHH

Choice Hotels

$68.45

0.25 (0.37%)

17:26
10/19/17
10/19
17:26
10/19/17
17:26
Hot Stocks
Frontier Communications named a Qualified Vendor with Choice Hotels Internationa »

Frontier Communications…

FTR

Frontier Communications

$11.48

0.02 (0.17%)

CHH

Choice Hotels

$68.45

0.25 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 08

    Nov

DRIO

DarioHealth

$1.98

-0.2 (-9.17%)

17:16
10/19/17
10/19
17:16
10/19/17
17:16
Syndicate
Breaking Syndicate news story on DarioHealth  »

DarioHealth files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUBI

Customers Bancorp

$33.16

0.46 (1.41%)

17:11
10/19/17
10/19
17:11
10/19/17
17:11
Hot Stocks
Customers Bancorp to spin off BankMobile business »

Customers Bancorp plans…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 15

    Nov

MVC

MVC Capital

$10.40

0.08 (0.78%)

17:07
10/19/17
10/19
17:07
10/19/17
17:07
Hot Stocks
MVC Capital: Glass Lewis, Egan-Jones against proposal to cease new investments »

MVC Capital announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

CELG

Celgene

$135.96

-1.21 (-0.88%)

17:05
10/19/17
10/19
17:05
10/19/17
17:05
Hot Stocks
Breaking Hot Stocks news story on Celgene »

Celgene down 6.6% after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

NGD

New Gold

$3.57

0.03 (0.85%)

17:03
10/19/17
10/19
17:03
10/19/17
17:03
Hot Stocks
New Gold says Rainy River Mine achieves commercial production »

New Gold reported that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.